MORGAN STANLEY PLC/CALL/BECTON DICKINSON AND CO./300/0.1/21.03.25 Stock

Warrant

DE000MG0Y1N9

Delayed Börse Stuttgart 04:13:14 2024-07-17 am EDT
0.35 EUR +6.06% Intraday chart for MORGAN STANLEY PLC/CALL/BECTON DICKINSON AND CO./300/0.1/21.03.25
Current month-17.50%
1 month-10.81%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-07-17 0.35 +6.06%
24-07-16 0.33 0.00%
24-07-15 0.33 -5.71%
24-07-12 0.35 +6.06%
24-07-11 0.33 +6.45%

Delayed Quote Börse Stuttgart

Last update July 17, 2024 at 04:13 am EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer Morgan Stanley
WKN MG0Y1N
ISINDE000MG0Y1N9
Date issued 2024-03-27
Strike 300 $
Maturity 2025-03-21 (248 Days)
Parity 10 : 1
Emission price 0.43
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.65
Lowest since issue 0.16
Spread 0.12
Spread %29.27%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
230.7 USD
Average target price
277.8 USD
Spread / Average Target
+20.42%
Consensus